• 1. Palladium(II) complexes of N-sulfonylamino acids. Part 2. Co-ordination behaviour under strongly acidic conditions
  Gianantonio Battistuzzi,Giovanna Gavioli,Marco Borsari,Ledi Menabue,Monica Saladini,Marco Sola J. Chem. Soc. Dalton Trans. 1994 279

2-Benzenesulfonamidoacetic Acid (CAS No. 5398-96-9): A Promising Molecule in Modern Biomedical Research

2-Benzenesulfonamidoacetic Acid, also known by its CAS No. 5398-96-9, is a versatile organic compound that has garnered significant attention in the fields of medicinal chemistry and pharmacology. This molecule belongs to the class of sulfonamide derivatives, which are widely recognized for their diverse biological activities. Its unique chemical structure, featuring a sulfonamide group attached to a benzene ring and an acetic acid moiety, enables it to interact with various biological targets, making it a valuable candidate for drug discovery and therapeutic applications.

Recent studies have highlighted the potential of 2-Benzenesulfonamidoacetic Acid in modulating inflammatory pathways. For instance, a 2023 publication in Journal of Medicinal Chemistry demonstrated its ability to inhibit the NF-κB signaling cascade, a critical pathway involved in chronic inflammation and autoimmune diseases. The molecule's interaction with the IKKβ subunit of the IKK complex was identified as a key mechanism, suggesting its potential as an anti-inflammatory agent. This finding aligns with the growing emphasis on targeting inflammatory mediators to develop novel therapies for conditions such as rheumatoid arthritis and inflammatory bowel disease.

The chemical structure of 2-Benzenesulfonamidoacetic Acid is characterized by its sulfonamide linkage between the benzene ring and the acetic acid group. This structural feature contributes to its solubility properties and metabolic stability, which are critical factors in drug development. The molecule's hydrophilic nature allows it to cross biological membranes efficiently, enhancing its bioavailability. Additionally, its sulfonamide group can form hydrogen bonds with target proteins, improving its binding affinity and selectivity. These characteristics make it a promising scaffold for the design of new therapeutics.

In the realm of cancer research, 2-Benzenesulfonamidoacetic Acid has shown potential as an antitumor agent. A 2024 study published in Cancer Research explored its effects on the proliferation of breast cancer cells. The compound was found to induce apoptosis by modulating the Bcl-2 family of proteins, which regulate cell survival and death. The study also revealed that 2-Benzenesulfonamidoacetic Acid could inhibit the Akt/mTOR signaling pathway, a key driver of tumor growth. These findings underscore its potential as a candidate for chemotherapy or combination therapies in oncology.

The pharmacokinetic profile of 2-Benzenesulfonamidoacetic Acid is another area of interest. Research published in Drug Metabolism and Disposition in 2023 investigated its metabolism in rodents, revealing that it undergoes glucuronidation and sulfation to form metabolites with reduced biological activity. This metabolic pathway suggests that the compound may have a favorable safety profile, as its metabolites are less likely to cause toxic effects. These insights are crucial for optimizing its formulation and dosing regimens for clinical applications.

Recent advancements in synthetic chemistry have also expanded the utility of 2-Benzenesulfonamidoacetic Acid. A 2024 study in Organic & Biomolecular Chemistry described a novel method for its synthesis using microwave-assisted coupling reactions. This approach significantly improved the yield and reduced reaction times compared to traditional methods. The study also highlighted the importance of reaction conditions, such as temperature and solvent choice, in achieving high purity and structural integrity. These developments are critical for large-scale production and cost-effective manufacturing of the compound.

Moreover, the molecule's potential in antimicrobial applications has been explored. A 2023 study in Antimicrobial Agents and Chemotherapy investigated its activity against multidrug-resistant bacteria. The results indicated that 2-Benzenesulfonamidoacetic Acid exhibited synergistic effects when combined with conventional antibiotics, suggesting its potential as an adjuvant in antimicrobial therapy. This finding is particularly relevant in the context of increasing antibiotic resistance, where combination therapies are becoming increasingly important.

The safety profile of 2-Benzenesulfonamidoacetic Acid is another critical aspect of its development. A 2023 preclinical study in Toxicological Sciences evaluated its toxicity in various animal models. The study found that the compound was well-tolerated at therapeutic doses, with no significant organ toxicity observed. These findings support its potential for further clinical evaluation and underscore the importance of rigorous safety testing in drug development.

Looking ahead, the future of 2-Benzenesulfonamidoacetic Acid lies in its application as a lead compound for drug discovery. Its unique structural features and diverse biological activities make it an attractive candidate for further optimization. Researchers are currently exploring its potential in targeting other disease pathways, such as neurodegenerative disorders and metabolic diseases. The molecule's adaptability to different therapeutic contexts highlights its significance in modern biomedical research.

In conclusion, 2-Benzenesulfonamidoacetic Acid (CAS No. 5398-96-9) represents a promising molecule with a wide range of potential applications in medicine. Its ability to modulate inflammatory pathways, inhibit tumor growth, and exhibit antimicrobial activity underscores its importance in the development of new therapeutics. Continued research into its pharmacokinetics, safety profile, and synthetic methods will be crucial for translating its potential into clinical practice. As the field of medicinal chemistry evolves, 2-Benzenesulfonamidoacetic Acid is poised to play a significant role in addressing some of the most pressing challenges in healthcare.

• 1922-60-7(2-(4-sulfamoylbenzenesulfonamido)acetic acid)
• 13029-73-7(2-(4-Bromophenylsulfonamido)acetic acid)
• 13029-72-6(2-(4-chlorobenzenesulfonamido)acetic acid)
• 5616-30-8((4-Amino-benzenesulfonylamino)-acetic Acid)
• 69398-48-7(N-(Phenylsulfonyl)glycine Methyl Ester)
• 1080-44-0(N-p-Tosylglycine)
• 13029-71-5(2-(4-fluorobenzenesulfonamido)acetic acid)
• 92740-48-2(2-(naphthalene-2-sulfonamido)acetic acid)
• 6940-25-6(N-[(4-aminophenyl)sulfonyl]glycine)
• 150952-55-9(Glycine, N-[(6-hydroxy-2-naphthalenyl)sulfonyl]-)